Your Article Summary
See Latest ArticlesFIGO stage IIIC endometrial carcinoma: Prognostic factors and outcomes
Gynecologic Oncology, 07/01/09
Hoekstra AV et al. - Endometrial cancer patients with FIGO stage IIIC had a 5-year OS of 61.3%, a RFS of 58.0% and a DSS of 71.9% in this series. Because of the high proportion of distant sites of recurrence (71.4%), recurrence outside the radiation field (100%), and mortality after recurrence (86.3%), multimodality therapy should be considered.
Related Articles
Local Biosynthesis of Estrogen in Human Endometrial Carcinoma through Tumor-Stromal Cell Interactions
Clinical Cancer Research, 10/06/09
Relevance Score: 70%
Endometrial Cancer
American Family Physician, 11/12/09
Relevance Score: 68%
p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes
Modern Pathology, 10/28/09
Relevance Score: 68%
Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction
Acta Obstetricia et Gynecologica Scandinavica, 10/09/09
Relevance Score: 67%
Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting
American Journal of Obstetrics and Gynecology, 10/08/09
Relevance Score: 67%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cervical cytology in patients with postmenopausal bleeding
Diagnostic Cytopathology, 11/30/09
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
Journal of Clinical Oncology, 11/30/09
Bevacizumab in the treatment of breast cancer
Cancer Treatment Reviews, 11/30/09